Trials / Completed
CompletedNCT00092885
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 831 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 15 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing symptoms of seasonal allergic rhinitis and asthma.
Detailed description
The duration of treatment is 2 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0476, montelukast sodium | |
| DRUG | Comparator: placebo |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2004-09-28
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00092885. Inclusion in this directory is not an endorsement.